GLP-1- based treatments for T2DM, such as GLP-1 receptor agonists, dual and triple agonists that activate GLP-1R, GIPR, and glucagon receptors, and dipeptidyl peptidase-4 (DPP-4) inhibitors have been reviewed here. In addition, we discuss the increase in the endogenous secretion of this hor...
GLP-1- based treatments for T2DM, such as GLP-1 receptor agonists, dual and triple agonists that activate GLP-1R, GIPR, and glucagon receptors, and dipeptidyl peptidase-4 (DPP-4) inhibitors have been reviewed here. In addition, we discuss the increase in the endogenous secretion of this hor...
DR patients treated with GLP-1 had their GLP-1R expression restored, their levels of pAKT and pERK1/2 decreased, and their levels of HDAC6 were also reduced [43]. Another study used NCI-H716 cells and ERK1/2 inhibitors to investigate how Sennoside A (SA) induces GLP-1 synthesis. GLP...
(CMCD).2These agents include, but are not limited to, sodium-glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) designed initially to lower hyperglycaemia (Figure1).1,...
While the exact signaling pathways underlying this effect have not been established, cAMP-raising agents such as forskolin similarly elevate somatostatin secretion, and application of PKA and EPAC2 inhibitors reduces glucose-stimulated somatostatin secretion [86]. Thus, cAMP pathways are active in delta...
Originally designed as anti-hyperglycemic drugs, Glucagon-Like Peptide-1 receptor agonists (GLP-1Ra) and Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have demonstrated protective cardiovascular effects, with significant impact on cardiovascular morbidity and mortality. Despite several mechanisms have be...
Examples of polysaccharide carriers include aminodextran. Examples of suitable polypeptide carriers include polylysine, polyglutamic acid, polyaspartic acid, co-polymers thereof, and mixed polymers of these amino acids and others, e.g., serines, to confer desirable solubility properties on the ...
We previously showed that aberrant histone modifications, including histone H3 lysine 4 (H3K4) and lysine 27 (H3K27) methylation, were associated with this lack of response and that epigenetic therapy with small molecule inhibitors of the H3K4 demethylase LSD1/KDM1A could reprogram AML cells to ...
Examples of peptides which have a high clearance are: ACTH, corticotropin-releasing factor, angiotensin, calcitonin, insulin, glucagon, glucagon-like peptide-1, glucagon-like peptide-2, insulin-like growth factor-1, insulin-like growth factor-2, gastric inhibitory peptide, growth hormone-releasing ...
These include thrombolytic therapy and angiotensin-converting enzyme (ACE) inhibitors. Thompson et al., M.J.A. 171; 153 (1999). PCT Application WO 98/08531 relates to treatment with GLP-1 of a patient suffering from Q-wave MI who is also incapable of auto-regulation of blood glucose. ...